PDL BioPharma (PDLI) Misses Q4 EPS by 15c, Authorizes Repurchase of $30M In Common Stock Through March 2018

PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of ($0.06), $0.15 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $66.5 million versus the consensus estimate of $56.37 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c